We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Plethora | PLE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.375 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.375 | 3.375 |
| Top Posts |
|---|
Posted at 11/3/2016 08:05 by lagosboy selling more likely to come from ex Ple holders looking to flip - hopefully JM & chums have HK investors lined up looking to take a stake. |
Posted at 19/2/2016 10:04 by catscats I think the MM are just playing with the PIs...they know that there will a steady stream of sellers who will be scared of holding HK or Frankfurt listed equity...and there will always be those who look at the discount to RP shares offer - think it is a steal and jump on. With a fat spread the MMs are making out...we all know that the RP share price will come down by 1/2 when the offer goes through...so u buy at 3.5p - get 15x RP shares (worth about 4.4p if RP shares are HK$0.035) and the gain is 25% - hardly worth the hassle of the transferring the shares to HK...and then there is the business risk...If investors thought otherwise then the shareprice of PLE would be at least 6p...but sadly that is not the case.... Of course I may be wrong and RP share stays at HK0.07 and PLE are a steal...but the market is not often that wrong IMHO |
Posted at 05/2/2016 15:54 by catscats lagosboy - I sincerely hope that Regent has/gets the cash to bring Fortacin to market but it is still a risk. If investors really thought PLE was worth more then the discount to Regent would not be so great.HK is not such a great market anymore - there are dozens of shares indefinitely suspended, and some really vicious sell offs in small caps (I know)...Maybe they can 'stir fry' the Regent/Fortacin story in HK (as the saying goes in HK)... |
Posted at 26/1/2016 10:33 by lagosboy To state within this release that investors should be cautious investing in Regent Pacific shares is a massive RED FLAG.I don't think so - appears bolierplate, last 2 years at RP have been profits warnings and before that suspension of trading so this year actually offers more hope for shareholders. If you believe the PE market offers a great commercial opportunity, Ple is still best placed, so good time to buy. Everyone is getting sppoked by share price action, but news from company has not changed - volumes are all pretty low. |
Posted at 26/1/2016 10:24 by cashmachine2 ZangdockTo state within this release that investors should be cautious investing in Regent Pacific shares is a massive RED FLAG. The reverse takeover of PLE by Regent is paper only and is now making PLE look massively overvalued. Maybe JM is hoping to conclude the takeover of PLE and then take RP private. |
Posted at 12/11/2015 17:28 by cashmachine2 Ch4p.It's more than a breakout! Whilst the share price was parked below 5p many naive investors bailed after they thought they'd been caught with the spike.You'll have those who panicked and those not comprehending why the share price isn't higher, followed by the nervous investors bailing as the share price moves north as they'll be relieved to break even! As seen today, sells were bought into and a 320k buy to take the stock from those sells!Instead of the share price faltering imo it'll head above the last placement of 9p and find a level around 10p. I think this is likely to happen very quickly |
Posted at 11/11/2015 14:17 by big_cat This is from Simon Thompson in Investors Chronicle this morning ....Plethora gets a boost The other news that caught my eye was the bid approach from Hong Kong-listed Regent Pacific (Hong Kong Stock Code: 575), the investment vehicle of Jim Mellon, for Aim-traded Plethora Solutions (PLE: 5p), a UK-based speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. Plethora's principal product is PSD502™, a prescription treatment for male premature ejaculation that obtained marketing authorisation from the European Commission in November 2013. Regent Pacific and its concert parties together already hold 29.88 per cent of Plethora's issued ordinary share capital and their indicative offer has been pitched at 15.7076 new Regent Pacific shares for each Plethora share. On the basis of Regent Pacific’s share price of HK$0.10, and using a sterling to Hong dollar exchange rate of £1:HK$11.71, the potential offer values each Plethora share at 13.4p, the company’s issued ordinary share capital at £110m and fully diluted share capital (excluding the out-of-money outstanding options and warrants) at £131m. This represents a thumping premium to Plethora’s sagging share price of 2.75p prior to news of the offer being made. But before you get too excited it’s worth flagging up that there is no cash element and Regent Pacific only has a market value of £30m. That’s less than Plethora’s market value of £41m and explains why there is such a big difference between the implied offer price of 13.4p a share and Plethora’s current share price of 5p. Still it’s fair to assume that a formal bid will be made as Regent Pacific has since received letters of intent from investors controlling 10.96 per cent of the Plethora’s issued share capital, so now has almost 41 per cent of the equity backing the bid. Clearly, it’s not going to be possible for everyone to buy Plethora’s shares in the London market at 5p, sit back and wait for the formal bid to be made, and then sell your Regent Pacific shares immediately at 13.4p in Hong Kong. If every investor attempts to do this then Regent Pacific’s share price will fall sharply given that it is issuing 15.4bn shares or more than four times its current issued share capital. That said, one of the reasons Plethora’s shares were so weak in the first place was down to the fact that the company is short of funds, so the price has been depressed due to financial distress. Eliminate this factor and a higher valuation is warranted. Prospects for PSD502™ Indeed, Plethora only has cash balances of £1m, and guidance is that commercial operations under its current operating plans will face a “significant negative impact in January 2016 in the absence of further funding being available to Plethora.” Regent Pacific has net cash and unpledged listed equity securities worth about £8.9m on its balance sheet which it can use in order to develop and commercialise PSD502™, and meet the substantial funding needs of Plethora in the near future. Moreover, it is desirable to progress with planned expenditure in key areas which support the development and commercialisation of PSD502™, such as manufacturing of a reduced fill can for the product, and research and development spend associated with a New Drug Application approval with the US regulator. A key objective is to obtain EU approval by 30 June 2016 for its reduced fill product, such that Plethora can obtain the variation payment of €6m from its European licence partner Recordati (REC:MIL), a €4.8bn pharmaceutical group listed on the Milan Stock Exchange, in preparation for its commercial launch in the EU; and firming up licenses for other territories too. Plethora’s board has had discussions with partners in Latin America, Asia Pacific and South Africa, and with a multi-national pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East. In all cases the parties have entered into non-binding heads of terms and have moved into discussions on the licence agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales. However, before negotiations can complete a reduced fill product for PSD502™has to be developed and manufactured under good manufacture practice conditions. And for that Plethora needs more funding. This is where Regent Pacific comes in. Implied value of Plethora Clearly, Mr Mellon and his concert party can see great potential in PSD502™otherwi Furthermore, it’s worth noting that Plethora self-developed this product and had not capitalised any of the costs incurred, nor any of the future value it may derive. Regent Pacific, with the assistance of a professional independent valuation expert, Jones Lang LaSalle Corporate Appraisal and Advisory, determined the fair value of PSD502™ based on the “relief from royalty method” to be in the region of US$253m, or £167m at current exchange rates. This explains why Regent Pacific’s indicative offer values Plethora’s equity north of £100m. Only time will tell whether this is a fair valuation or not. Frankly, whether or not PSD502™ is a success is not the issue here. I am far more concerned as to what will happen to Regent Pacific’s share price if it launches a formal bid and Plethora shareholders are then issued with a slug of equity. Realistically I can see the price in Hong Kong soften, but certainly not deflate by 60 per cent which is the implied discount in Plethora’s share price. In fact, I reckon that if Regent Pacific launches a bid there could be upwards of 50 per cent upside to Plethora’s current share price of 5p. The interest of Hong Kong investors is being aroused by the potential acquisition too which explains why Regent Pacific’s share price has perked up since news of its bid approach emerged. At around the 5p level, Plethora shares are worth having a small interest in. Speculative buy. |
Posted at 11/11/2015 10:02 by tsmith2 Plethora (PLE) was a company that I was only vaguely aware of up until last week when a potential takeover bid was made for it. Up until then this AIM-listed pharmaceutical company, whose main product is a premature ejaculation treatment, had been trading at between 3p and 4 p, but then an offer landed from Hong Kong investment vehicle, Regent Pacific (also listed in Frankfurt but volume there is almost non-existent), that valued Plethora at 12.5p per share.The offer wasn’t quite as random as it might first have appeared as the two companies have close links, and Jim Mellon and his Regent Pacific vehicle, plus other interests he has, own just under 30% of Plethora. The share price rocketed to over 7p on the day of this news, but has since dropped back to the current level of around 5p. That might seem strange until you look at the deal in more detail and see that it is an all-paper offer, with Plethora holders getting 15.7076 Regent shares for every share that they hold. That made it far less certain that the deal will ultimately be worth 12.5p, if and when it is finalised, and many private investors didn’t seem too keen on possibly ending up with Hong Kong listed stock and sold into the spike. Since then we have seen a continued sell-off of Plethora shares – probably partly from people who bought near the top of the spike and then sold because it didn’t hit 12.5p overnight! – and that has included one of the institutional holders, Baker Brothers, selling a small amount of its holding. What we haven’t seen though, and which has surprised me, is any sort of sell off of Regent shares in Hong Kong, where the share price has remained steady at around HK0.1. This suggests to me that Regent investors are keen on the deal and see it as offering value. Currently Regent has cash but is looking for an investment to generate revenue, and Plethora has a finished product but is desperately short of money. Both share prices are at their lowest levels for sometime and have been a lot higher in recent times, so it could be that the market is viewing the combined entity as likely to be far stronger than the sum of the two separate parts. For me this is all about the potential opportunity being offered by the low Plethora price if the deal goes ahead as planned, and I have been buying at just over 5p on that basis – having watched the reaction in Hong Kong before taking a position. I would expect that those who don’t want to end up with Hong Kong listed shares will sell out before any deal is done, but it is also likely that we will see selling pressure on Regent after the deal due to the huge number of new shares issued. Although there are relatively few Plethora shares are in freefloat and a lot of the outstanding warrants won’t come into play – a chunk of those are owned by parties related to Jim Mellon and Regent so can’t be exercised during a bid period, and the ones from the last placing are at 15p so aren’t currently relevant – so we may not see as much of a sell-off of Regent shares as some might be expecting. The Regent price would also have to collapse to around HK0.04 as well to make it equivalent to the current Plethora price of 5p! Should the deal be finalised and go to a vote it should be a formality that it goes through, as the board has recommended it be accepted and Regent has already received a letter of intent from two big holders pledging support through voting rights on over 10% of the shares in issue. There is of course some risk that this could go lower, but from the current level I personally see good risk versus return, whether you are in for a trade or holding until after the deal is done. - See more at: hxxp://www.shareprop |
Posted at 10/11/2015 08:46 by catscats you have to ask why the share price sits at such a large discount to the offer...?1. investors selling because they dont want to hold HK stock - possible 2. investors think the deal will not go ahead - unlikely 3. investors think the price of Regent will halve when deal is done - v likely Important question remains - what is PLE's treatment worth....? Tricky.... |
Posted at 05/11/2015 14:10 by gotabsirius Smithie - Ok cheers and I appreciate that but as the deal approaches, large multi national investors will buy any discrepancy in the price as they will be able to trade this in HK.The longer time goes on more likely the gap will close and private investors in the UK should have plenty of time to sell after deal is officially made and before the company is delisted. imho we should get 10-12p minimum before delisting. This is, of course, if you think the deal will go ahead which is where some doubt may lye and one reason why the price is still at a discount to the offer. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
